Background-Adrenomedullin (AM) is a potent pulmonary vasodilator peptide. However, whether intratracheal delivery of aerosolized AM has beneficial effects in patients with idiopathic pulmonary arterial hypertension remains unknown. Accordingly, we investigated the effects of AM inhalation on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Methods and Results-Acute hemodynamic responses to inhalation of aerosolized AM (10 g/kg body wt) were examined in 11 patients with idiopathic pulmonary arterial hypertension during cardiac catheterization. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM or placebo. 
I
diopathic pulmonary arterial hypertension is a rare but life-threatening disease characterized by progressive pulmonary hypertension, ultimately producing right heart failure and death. 1, 2 Although a variety of vasodilators have been proposed as potential therapy for this disease over the past 30 years, [3] [4] [5] [6] [7] some patients ultimately require heart-lung or lung transplantation. 8, 9 Thus, a novel therapeutic strategy is desirable.
Adrenomedullin (AM) is a potent, long-lasting vasodilator peptide that was originally isolated from human pheochromocytoma. 10 Immunoreactive AM has subsequently been detected in plasma and a variety of tissues, including blood vessels and lungs. 11, 12 It has been reported that there are abundant binding sites for AM in the lungs. 13 We have shown that the plasma AM level increases in proportion to the severity of pulmonary hypertension and that circulating AM is partially metabolized in the lungs. 14, 15 Interestingly, AM has been shown to inhibit the migration and proliferation of vascular smooth muscle cells. 16, 17 These findings suggest that AM plays an important role in the regulation of pulmonary vascular tone and vascular remodeling. In fact, we have shown that short-term intravenous infusion of AM significantly decreases pulmonary vascular resistance in patients with congestive heart failure 18 or pulmonary arterial hypertension. 19 Unfortunately, however, intravenously administered AM induced systemic hypotension in such patients because of nonselective vasodilation in the pulmonary and systemic vascular beds.
More recently, inhalation of aerosolized prostacyclin and its analogue iloprost has been shown to cause pulmonary vasodilation without systemic hypotension in patients with idiopathic pulmonary arterial hypertension. 20, 21 In addition, inhalant application of vasodilators does not impair gas exchange because the ventilation-matched deposition of drug in the alveoli causes pulmonary vasodilation matched to ventilated areas. 20 In clinical settings, inhalation therapy may be more simple, noninvasive, and comfortable than continuous intravenous infusion therapy. Thus, the purpose of the present study was to investigate the effects of AM inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
Methods

Study Subjects
Eleven patients with idiopathic pulmonary arterial hypertension (9 women and 2 men; age, 39Ϯ3 years) were included in this study. Idiopathic pulmonary arterial hypertension was defined as pulmonary hypertension unexplained by any secondary cause, on the basis of the criteria of the National Institutes of Health registry. 1 Ten patients were classified as New York Heart Association (NYHA) functional class III and 1 as class IV (Table 1 ). Two of the 11 patients (18%) were acute responders who showed a significant decrease in mean pulmonary arterial pressure of Ն20% with a decrease in mean pulmonary arterial pressure to Ͻ35 mm Hg and no change or an increase in cardiac index during short-term infusion of epoprostenol. Long-term medication, including anticoagulant agents, digitalis, and diuretics, was kept constant. Vasodilator agents, such as oral prostacyclin analogue and calcium antagonists, were stopped Ն12 hours before the study procedure was begun. The ethics committee of the National Cardiovascular Center approved the study, and all patients gave written informed consent.
Preparation of Human AM
Human AM was dissolved in saline with 4% D-mannitol and sterilized by passage through a 0.22-m filter (Millipore Co). At the time of dispensing, randomly selected vials were submitted for sterility and pyrogen testing. The chemical nature and content of the human AM in vials were verified by high-performance liquid chromatography and radioimmunoassay. All vials were stored frozen at Ϫ80°C from the time of dispensing until the time of preparation for administration.
Hemodynamic Studies
Acute hemodynamic responses to AM inhalation were assessed in all patients while they were in a stable condition during hospitalization. Hemodynamic variables, including pulmonary arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, and cardiac output (in triplicate), were determined with a thermodilution catheter (TOO21H-7.5F, Baxter Co). 22 A 22-gauge cannula was inserted into a radial artery for hemodynamic measurements and blood sampling. After an equilibration period of 30 minutes, baseline hemodynamics were measured. Then, AM (10 g/kg body wt) was inhaled as an aerosol with a jet nebulizer (Porta-Nebu, MEDIC-AID) for 15 minutes, which resulted in a cumulative dose of 400 to 600 g AM. Hemodynamic parameters were measured at 15-minute intervals starting 15 minutes before AM inhalation until 60 minutes after inhalation. Blood samples for AM measurement were taken at 15-minute intervals from 15 minutes before inhalation until 60 minutes after the end of inhalation.
Cardiopulmonary Exercise Testing
The effects of AM inhalation on exercise capacity were examined in 10 of 11 patients; 1 patient with NYHA class IV underwent the 6-minute walk test according to decision of attending physicians. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM (10 g/kg body wt) or saline in a double-blind, randomized, crossover design. This study was performed on 2 separate days, 1 week apart. The first cardiopulmonary exercise testing was performed within 10 days after the cardiac catheterization. The patients performed exercise seated on a cycle ergometer. They first pedaled at 55 rpm without any added load for 1 minute. The work rate was then increased by 15 W/min up to the symptom-limited maximum. Breath-by-breath gas analysis was performed with an AE280 (Minato Medical Science) connected to a personal computer running analyzing software. 23 The ratio of change in oxygen uptake to that in work rate (⌬V O 2 /⌬W ratio) was calculated as the slope of oxygen consumption per unit workload from 1 minute after the start of load addition until 85% maximal V O 2 . Exercise capacity was evaluated by peak oxygen consumption (peak V O 2 ), which was defined as the value of averaged data during the final 15 seconds of exercise. Ventilatory efficiency during exercise was represented by the V E-V CO 2 slope, which was determined as the linear regression slope of V E and V CO 2 from the start of exercise until the RC point (the time until which ventilation is stimulated by CO 2 output and end-tidal CO 2 tension begins to decrease).
Measurement of Plasma AM, cAMP, and cGMP
Blood samples were immediately transferred into chilled glass tubes containing disodium EDTA (1 mg/mL) and aprotinin (500 U/mL) and centrifuged immediately at 4°C, and the plasma was frozen and stored at Ϫ80°C until assayed. Plasma AM level was measured by a specific immunoradiometric assay kit (Shionogi Pharmaceutical Co Ltd). 24 Plasma cAMP and cGMP were determined with radioimmunoassay kits (cAMP assay kit, cGMP assay kit, Yamasa Shoyu). 18 
Statistical Analysis
All data were expressed as meanϮSEM unless otherwise indicated. Changes in hemodynamic and hormonal parameters by AM inhalation were analyzed by 1-way ANOVA for repeated measures, 
Results
All patients tolerated this study protocol. One patient developed a headache, and another patient had mild arterial hypoxemia during AM inhalation. None of them experienced other adverse effects, such as systemic hypotension, infection, or arrhythmia.
Plasma AM Level After Inhalation
Baseline plasma AM level in patients with idiopathic pulmonary arterial hypertension was significantly higher than the normal value, which was determined from pooled data of 15 age-matched healthy subjects (11.9Ϯ0.8 versus 9.3Ϯ0.1 fmol/mL, PϽ0.05). Inhalation of AM significantly increased the plasma AM level to 22.9Ϯ2.1 fmol/mL immediately after inhalation (Figure 1) . The half-life of plasma AM after inhalation was approximately 20 minutes, and the elevation of AM lasted for Ͼ45 minutes. Plasma cAMP level increased significantly 30 minutes after the initiation of AM inhalation (10.8Ϯ0.7 to 12.0Ϯ0.6 pmol/mL, PϽ0.05), although plasma cGMP level was not significantly altered (6.5Ϯ1.0 to 6.8Ϯ1.0 pmol/mL, PϭNS).
Hemodynamic Effects of AM Inhalation
Inhalation of AM significantly decreased mean pulmonary arterial pressure in patients with idiopathic pulmonary arterial hypertension (54Ϯ3 to 47Ϯ3 mm Hg, PϽ0.05) without a significant decrease in mean arterial pressure (85Ϯ4 to 83Ϯ4 mm Hg, PϭNS) (Figure 2 (Figure 3 ). Inhaled AM did not significantly alter systemic vascular resistance. The ratio of pulmonary vascular resistance to systemic vascular resistance was decreased significantly at the end of inhalation (0.63Ϯ0.08 to 0.55Ϯ0.07, PϽ0.05). These hemodynamic effects of AM lasted for Ͼ45 minutes.
No significant change in heart rate, pulmonary capillary wedge pressure, or right atrial pressure was observed. There was no significant change in arterial oxygen saturation (94Ϯ3% to 93Ϯ3%).
Effects of AM Inhalation on Exercise Capacity and Ventilatory Efficiency
As the limiting symptom at the end of exercise, 6 patients reported muscle weakness and 4 reported dyspnea. There was no difference in these symptoms when exercise testing was performed with or without inhalation of AM. Inhalation of AM altered neither heart rate nor blood pressure either at rest or at peak exercise ( Table 2) . Inhalation of AM significantly increased peak workload (86Ϯ5 to 93Ϯ6 W, PϽ0.05) ( Table  2 ). AM also significantly increased peak V O 2 (14.6Ϯ0.6 to 15.7Ϯ0.6 mL · kg Ϫ1 · min Ϫ1 , PϽ0.05) (Figure 4) . Inhalation of AM significantly increased ⌬V O 2 /⌬W ratio (6.3Ϯ0.4 to 
7.0Ϯ0.5 mL · min
Ϫ1 · W Ϫ1 , PϽ0.05). AM did not significantly alter the V E-V CO 2 slope (Table 2) . No significant changes in arterial oxygen saturation were observed either at rest or at peak exercise. In 1 patient with NYHA class IV who did not undergo cardiopulmonary exercise testing, the distance walked in 6 minutes increased from 150 to 180 m by inhalation of AM.
Discussion
In the present study, we demonstrated that inhalation of AM improved hemodynamics with pulmonary selectivity and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
AM is one of the most potent endogenous vasodilators in the pulmonary vascular bed. [25] [26] [27] The vasodilatory effect is mediated by cAMP-dependent and nitric oxide-dependent mechanisms. 28, 29 Endogenous AM production is enhanced in a variety of cardiovascular diseases through a compensatory mechanism. 14, 30 Nonetheless, additional supplementation of AM has beneficial effects in these diseases. 18, 19 These results suggest that endogenous AM level is not sufficient to improve deteriorated conditions despite the increased AM production. Interestingly, Champion et al 31 have shown that intratracheal gene transfer of calcitonin gene-related peptide, a member of the same peptide family as AM, to bronchial epithelial cells attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. These results raise the possibility that intratracheal delivery of a vasodilator peptide may be sufficient to alter pulmonary vascular function. In fact, in the present study, inhalation of AM significantly decreased pulmonary vascular resistance, whereas it did not alter systemic arterial pressure or systemic vascular resistance. The ratio of pulmonary vascular resistance to systemic vascular resistance was reduced significantly by AM inhalation. These results suggest that inhaled AM improves hemodynamics with pulmonary selectivity. This is consistent with earlier findings that inhaled prostacyclin or its analogue iloprost acts transepithelially with pulmonary selectivity and improves pulmonary hypertension. 20, 21 Inhalation of AM slightly but significantly increased cardiac index in patients with idiopathic pulmonary arterial hypertension. Considering the strong vasodilator activity of AM in the pulmonary vasculature, the significant decrease in cardiac afterload may be responsible for increased cardiac index with AM. Interestingly, the hemodynamic effects of inhaled AM lasted for Ͼ45 minutes. A previous study demonstrated that intravenous injection of AM produces a longlasting vasodilator response because of its long half-life (Ϸ15 minutes). 32 The half-life of plasma AM after inhalation was longer (20 minutes). Thus, inhalation of AM may cause relatively long-lasting pulmonary vasodilator activity in patients with idiopathic pulmonary arterial hypertension. In the present study, plasma cAMP level increased after AM inhalation, suggesting that the hemodynamic effects of AM may be mediated by activation of cAMP.
Earlier studies have shown that peak V O 2 during exercise is markedly lower in patients with idiopathic pulmonary arterial hypertension than in healthy subjects. 33, 34 Peak V O 2 is determined primarily by the maximal cardiac output during exercise and the potential for O 2 extraction by the exercising muscle. 35 Thus, the decreased peak V O 2 may reflect insufficient oxygen delivery to the body during exercise, at least in part because of an inadequate increase in cardiac output under conditions of severe pulmonary hypertension. In the present study, inhalation of AM significantly increased peak V O 2 in patients with pulmonary hypertension. AM also increased the ⌬V O 2 /⌬W ratio, which indicates oxygen transport per unit workload to the exercising legs. These results suggest that inhalation of AM improves exercise capacity in patients with idiopathic pulmonary arterial hypertension. It is possible that an increase in cardiac output during exercise may contribute to increases in peak V O 2 and the ⌬V O 2 /⌬W ratio.
The major limitation of this pilot trial relates to the lack of a randomized, placebo-controlled group in acute hemodynamic studies, which was as result not only of invasive assessment of hemodynamics but also of the limited number of patients available. Nevertheless, cardiopulmonary exercise testing was performed in a double-blind, randomized, crossover design. Thus, it is unlikely that the hemodynamic effects of inhaled AM are attributable to the placebo effect.
Inhalation therapy may be more simple, noninvasive, and comfortable than continuous intravenous infusion therapy. An experimental study demonstrated that repeated inhalation of AM (for 30 minutes, 4 times a day) inhibited monocrotaline-induced pulmonary hypertension and markedly improved survival in rats. 36 Recently, pulmonary delivery of a dry-powder insulin has been shown to improve glycemic control without adverse pulmonary effects. 37 Although further studies are necessary to maximize the efficiency and reproducibility of pulmonary AM delivery, combining AM inhalation therapy with other modalities that have a different mode of action may have beneficial effects in patients with idiopathic pulmonary arterial hypertension.
Conclusions
These preliminary results suggest that inhalation of AM may have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.
